MK-4409

MK-4409
Clinical data
ATC code
  • None
Legal status
Legal status
Identifiers
PubChem CID
ChemSpider
ChEMBL
Chemical and physical data
Formula C22H17FN3O2S
Molar mass 441.905 g/mol
3D model (JSmol)

MK-4409 is a drug which acts as a potent and selective inhibitor of the enzyme fatty acid amide hydrolase (FAAH), with an IC50 of 11nM, and both analgesic and antiinflammatory effects in animal studies. It was developed for the treatment of neuropathic pain and has progressed as far as early stage human clinical trials.[1][2]

See also

References

  1. Chobanian; et al. (10 April 2014). "Discovery of MK-4409, a Novel Oxazole FAAH Inhibitor for the Treatment of Inflammatory and Neuropathic Pain". ACS Med. Chem. Lett.
  2. Merck (15 October 2009). "Merck Pipeline, Oct 2009" (PDF). Merck.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.